Merck Company Stock Cash And Equivalents
| 0QAH Stock | USD 103.50 27.80 21.17% |
Merck Company fundamentals help investors to digest information that contributes to Merck's financial success or failures. It also enables traders to predict the movement of Merck Stock. The fundamental analysis module provides a way to measure Merck's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merck stock.
Merck | Cash And Equivalents |
Merck Company Company Cash And Equivalents Analysis
Merck's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Merck Cash And Equivalents | 7 B |
Most of Merck's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merck Company is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Merck Company has 7 B in Cash And Equivalents. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United Kingdom stocks is 159.06% lower than that of the firm.
Merck Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merck's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merck could also be used in its relative valuation, which is a method of valuing Merck by comparing valuation metrics of similar companies.Merck is currently under evaluation in cash and equivalents category among its peers.
Merck Fundamentals
| Return On Equity | 0.0761 | ||||
| Return On Asset | 0.0512 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 286.09 B | ||||
| Shares Outstanding | 2.54 B | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 77.64 % | ||||
| Price To Book | 8.24 X | ||||
| Price To Sales | 4.50 X | ||||
| Revenue | 60.12 B | ||||
| Gross Profit | 42.08 B | ||||
| EBITDA | 12.33 B | ||||
| Net Income | 365 M | ||||
| Cash And Equivalents | 7 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 1.37 B | ||||
| Debt To Equity | 1.16 % | ||||
| Book Value Per Share | 15.24 X | ||||
| Cash Flow From Operations | 13.01 B | ||||
| Earnings Per Share | 1.22 X | ||||
| Price To Earnings To Growth | 0.10 X | ||||
| Number Of Employees | 67 K | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 262.63 B | ||||
| Total Asset | 106.67 B | ||||
| Retained Earnings | 53.9 B | ||||
| Working Capital | 6.47 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.07 % | ||||
| Net Asset | 106.67 B | ||||
| Last Dividend Paid | 2.84 |
About Merck Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merck Company's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck Company based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.